1、 : , : 120 , 60 , 4 , 3 , 4 , , , N BNP (N-terminal-pro BNP, NT-pro BNP) , (plasma renin aetivity, PRA) , (aldosterone, ALD) , (homocysteic acid, HCY) , , : (91.67%) , (81.67%) , -pro BNP , , (P0.05) : , RAAS HCY , , , ; ; - - (RAAS ) ; ; , , , , E-mail: Clinical Efficacy of Tongbu Xinbao Capsule on
2、 Qi Deficiency Blood Stasis and Water Flux Type Chronic Heart Failure JIA Jun-bing FAN Rui-hong Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital; Abstract Objective: To observe the clinical efficacy of Tongbu Xinbao capsule on chronic heart failure ( Qi deficiency blood stasis and
3、 water flux type) , in order to investigate the mechanism of Tongbu Xinbao capsule on chronic heart failure. Method: A total of 120 patients with chronic heart failure outpatients or inpatient patients were randomly divided into treatment group and control group, with 60 cases in each group. The con
4、trol group got western medicine for basic treatment; in addition to the therapy of the control group, the treatment group was also given Tongbu Xinbao capsule, 4 capsule, tid, for 4 weeks. After the treatment, the clinical efficacy of the two groups were observed; and before and after treatment, sym
5、ptom score, N-terminal-pro BNP ( NT-pro BNP) , plasma renin aetivity acid ( HCY) levels were observed, and the blood, urine, stool routine, liver and kidney function and other laboratory parameters were detected to determine the toxic and side effects of Tongbu Xinbao capsule. Result: Efficacy of tr
6、aditional Chinese medicine ( TCM) syndrome of treatment group was 91. 67%, which was significantly higher than 81. 67% of control , NT-pro BNP were significantly decreased than before treatment, and those in the treatment group were superior to those of the control group ( P 0. 05) . Conclusion:Conv
7、entional western medicine combined with Tongbu Xinbao capsule showed a significant therapeutic effect, suggesting that the combined administration can better inhibit RASS activity and reduced HCYof patients with heart failure, which may be related to the inhibition of PRA, Ang11, ALD, HCY, with no t
8、oxic or side effect and a reliable efficacy. Keyword Tongbu Xinbao capsule; heart failure; rennin angiotensin aldosterone system (RAAS system) ; homocysteine; (chronic heart failure, CHF) , , , , 400 , 0.9%1, 2 CHF , , , 3, - - (RAAS ) , , , , ( ) , , 4, CHF , CHF , 5-8, , , , 40 , , , CHF 9, , , CH
9、F , N BNP (NT-pro BNP) , (PRA) , (ALD) , (HCY) , CHF 1 1.1 2014 9 2017 5 CHF 120 , , 60 33 , 27 ; , , 36 , 24 , 23 37 ; 31 , 29 ; , ) , 40 , 20 , 25 35 , , ( 2014YN020) 1.2 1.2.1 2014 10 (NYHA) , , , , ; , , , 1.2.2 11 , , , , , ; , , , , , , , 2 1 , 1.3 (1) ; (2) ; (3) NYHA ; (4) 4575 ; (5) 1.4 (1)
10、 ; (2) ; (3) ; (4) ; (5) 1.5 , , , , ( , ) , ( , H20030514, 10 mg/ ) 10 mg/ , 1 1 (qd) , ( , H20040217, 80 mg/ ) 80 mg/ , qd, ( , H32025391, 25 mg/ ) 12.5 mg/ , 1 2 (bid) , ( , H31020678, 0.25 mg/ ) 0.125 mg/ , qd, ( , H10940039 20 mg/ ) 20 mg/ , bid, ( , H12020163, 20 mg/ ) 20 mg/ , qd, ( , H330200
11、70, 20 mg/ ) 20mg/ , qd, , , (2001) Z 0429 , 0.42 g/ , 4 , 3 , 4 1 1.6 , , , , , 1.6.1 PR -pro BNP , , 05877082001, 08157102001, 05917062001, 05494032001;HCY , , BC117012, , 4 1.6.2 , IE33 ( Philips ) , (LVPWT) , (IVST) , (LVDd) , 5 , , Devereux (LVMI) 1.6.3 11 , , , I , 2 ; , , 1 2 ; , , , 30%, 1 1
12、.7 SPSS 13.0 , , t , % , , P0.05 2 2.1 (P0.05) ; (P0.05) 1 1 values of traditional Chinese medicine (TCM) syndromes in both groups 2.2 (91.67%) , (81.67%) (P0.05) 2 2 Table 2Comparison of curative effect of TCM in two groups of patients 2.3 (88.33%) , (78.33%) (P0.05) 3 2.4 -pro BNP , -pro BNP (P0.0
13、5) , , -pro BNP (P0.05) 4 3 Table 3 Comparison of cardiac function between two groups 2.5 , ; 5 4 -pro BNP -pro BNP levels before =60) 5 in echocardiographic parameters before and after treatment in both groups 2.6 , , 3 CHF , , , , , , , , 12-16, (PRA) , (ALD) RAAS , , , 17 , : , ( ) , , , , , CHF
14、, , CHF , , , , , , , CHF , , CHF , , , , , , , , , , , , , , , ; , ; , , , , , , , , , ; , , ; , ; , , , , , , ; 10 , , , , 18-21; , , , , 22; , ; , 23, , , 24, 18 B2, B12 25; RAAS 26 , , HCY , , RAAS HCY , , , , , , , , , , 1 , , , . J. , 2012, 26 (10) :937-938. 2 . J. , 2015, 3 (1) :244-246. 3 . (1) - J. , 2005, 20 (5) :323-324. 4 , , , . J. , 2016, 14 (8) :841-843. 5 , . J. , 2015, 21 (1) :178-181. 6 , ,
